Opko Health financials
$1.62−0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.9M | $713.1M | $863.5M | $1.00B | $1.77B | $1.44B | $901.9M | $990.3M | $966.0M | $1.12B |
| Gross profit | $205.9M | $218.5M | $318.1M | $288.2M | $581.5M | $541.0M | $329.5M | $385.6M | $345.9M | $506.0M |
| Gross margin | 33.9% | 30.6% | 36.8% | 28.7% | 32.8% | 37.7% | 36.5% | 38.9% | 35.8% | 45.3% |
| Operating income | -$219.0M | -$273.6M | -$157.0M | -$244.8M | -$12.8M | $57.7M | -$274.1M | -$171.2M | -$276.4M | -$96.6M |
| Net income | -$225.7M | -$53.2M | -$188.9M | -$328.4M | -$30.1M | $30.6M | -$314.9M | -$153.0M | -$305.3M | -$48.4M |
| Net margin | −37.2% | −7.5% | −21.9% | −32.7% | −1.7% | 2.1% | −34.9% | −15.5% | −31.6% | −4.3% |
| Diluted EPS | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 | $-0.53 | $-0.27 | $-0.55 | $-0.08 |
| EBITDA | -$127.4M | -$175.4M | -$51.7M | -$137.5M | $64.3M | $139.1M | -$102.7M | -$68.9M | -$164.6M | $17.0M |
| Operating cash flow | -$178.5M | -$183.5M | -$28.2M | -$95.2M | $40.0M | $39.5M | -$172.5M | -$109.1M | -$92.1M | $32.0M |
| Free cash flow | -$190.8M | -$208.5M | -$44.5M | -$119.8M | $7.9M | $5.8M | -$185.3M | -$137.0M | -$138.6M | $13.5M |
| Diluted shares | 751.1M | 694.0M | 751.8M | 719.1M | 648.1M | 640.7M | 595.5M | 563.1M | 559.2M | 555.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $369.1M | $431.9M | $95.9M | $153.2M | $134.7M | $72.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $341.7M | $434.2M | $241.6M | $247.0M | $202.6M | $246.7M |
| Total assets | $1.93B | $2.20B | $2.01B | $2.17B | $2.40B | $2.47B |
| Total liabilities | $664.0M | $834.8M | $622.5M | $605.6M | $714.6M | $801.5M |
| Shareholders' equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B | $1.67B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology